Literature DB >> 12555675

A single dose of oral DNA immunization delivered by attenuated Salmonella typhimurium down-regulates transgene expression in HBsAg transgenic mice.

Bo Jian Zheng1, Mun Hon Ng, Kwok Wah Chan, Sidney Tam, Patrick C Y Woo, Sze Park Ng, Kwok Yung Yuen.   

Abstract

The efficacy of immunization with Salmonella typhimurium aroA to deliver the plasmid pRc/CMV-HBsAg (i.e. an oral DNA vaccine) was compared with that of intramuscular immunization with the same plasmid DNA, and with recombinant HBsAg protein, in a HBsAg transgenic mouse model. A single dose of oral DNA vaccine evoked vigorous Th1 cell and CTL responses and production of IgG2 subclass of anti-HBs after 2 weeks, and this was accompanied by a transient hepatitic flare with elevated alanine aminotransferase in the first 3 weeks. Concomitantly, the level of HBsAg-mRNA in liver tissues decreased by more than fourfold and viral-antigen expression was curtailed markedly in hepatocytes compared with controls. Hepatitic flare subsided after 3 weeks, but suppression of the transgene expression was continued in the absence of overt liver pathology for the remaining duration of the experiment (i.e. 12 weeks), and possibly beyond. The other vaccines could also break immune tolerance, but this was achieved only after repeated booster doses of the respective vaccines, and they did not affect transgene expression, or induce hepatic flare. We previously showed in non-transgenic mice that immunization by the oral DNA vaccine is achieved by an active intestinal infection with a bacterial carrier that is an adept intracellular parasite, and the immune response to the vaccination is orchestrated by phagocytic APC. Our present findings further implicated that the combined effects of an innate and a specific immune response induced by oral DNA vaccination are crucial in down-regulating HBsAg-transgene expression in hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12555675     DOI: 10.1002/1521-4141(200211)32:11<3294::AID-IMMU3294>3.0.CO;2-D

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  4 in total

1.  A DNA prime, orally delivered protein boost vaccination strategy against viral encephalitis.

Authors:  Mark P Zanin; Diane E Webster; Steven L Wesselingh
Journal:  J Neurovirol       Date:  2007-06       Impact factor: 2.643

2.  Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.

Authors:  Lanying Du; Guangyu Zhao; Yongping Lin; Hongyan Sui; Chris Chan; Selene Ma; Yuxian He; Shibo Jiang; Changyou Wu; Kwok-Yung Yuen; Dong-Yan Jin; Yusen Zhou; Bo-Jian Zheng
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

3.  SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.

Authors:  Patrick C Y Woo; Susanna K P Lau; Hoi-Wah Tsoi; Zhi-Wei Chen; Beatrice H L Wong; Linqi Zhang; Jim K H Chan; Lei-Po Wong; Wei He; Chi Ma; Kwok-Hung Chan; David D Ho; Kwok-Yung Yuen
Journal:  Vaccine       Date:  2005-10-10       Impact factor: 3.641

4.  Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt.

Authors:  Amani A Saleh; Mohamed A Saad; Islam Ryan; Magdy Amin; Mohamed I Shindy; Wael A Hassan; Mahmoud Samir; Ayman A Khattab; Sherein S Abdelgayed; Mohamed G Seadawy; Hossam M Fahmy; Khaled Amer
Journal:  Antib Ther       Date:  2021-06-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.